Integrated Diligence for Complex Healthcare Assets

Complex healthcare assets cannot be evaluated through market sizing and competitive analysis alone. Their value depends on the underlying science, disease epidemiology and etiology, product performance, clinical evidence, regulatory and reimbursement pathways, delivery economics, and likelihood of adoption.

We integrate technical, scientific, and commercial due diligence into a single assessment. Each finding is translated into its implications for the forecast, valuation, transaction risk, and post-close priorities.

Our work spans MedTech, molecular diagnostics, digital health, large-molecule biologics, and advanced-modality therapeutics.

What We Evaluate

  • Scientific and technical foundations: Disease biology, mechanism of action, biomarker rationale, product performance, manufacturing requirements, scalability, and technical limitations.
  • Clinical evidence: Target populations, epidemiology, study design, endpoints, comparators, safety and efficacy, clinical utility, durability, generalizability, and remaining evidence gaps.
  • Regulatory, reimbursement, and pricing: Regulatory pathway and claims, coding, coverage, payment, payer evidence requirements, HTA considerations, site-of-care economics, and pricing feasibility.
  • Market and adoption: Addressable populations, patient flow, competitive position, customer segmentation, channels, clinical workflow, institutional adoption, and the KOL, society, and guideline landscape.
  • Transaction economics: Forecast assumptions, risk-adjusted scenarios, valuation implications, potential synergies, value-creation opportunities, and integration priorities.

For Venture Capital, Private Equity, and Strategic Acquirers

We provide independent buy-side diligence for investors and acquirers evaluating complex healthcare companies, technologies, and individual assets. Our analysis tests whether the scientific, clinical, reimbursement, and adoption assumptions support the investment thesis.

Our support includes:

  • Integrated technical and commercial due diligence
  • Investment-thesis and investment-committee support
  • Market, epidemiology, and revenue-forecast validation
  • Primary research with clinicians, payers, administrators, and KOLs
  • Reimbursement, pricing, and adoption-risk assessment
  • Transaction and valuation support
  • Post-merger integration and value-creation planning

For Investment Banks and Transaction Advisors

We provide vendor-side diligence for companies and bankers preparing healthcare assets for market. We identify issues before buyers do, strengthen the evidence supporting the commercial case, and prepare a defensible view of the asset’s opportunity and risks.

Our support includes:

  • Independent vendor due diligence
  • Technical and commercial asset assessment
  • Market sizing and forecast validation
  • Evidence-based asset positioning and transaction narrative
  • Identification and mitigation of evidence, reimbursement, and adoption risks
  • Data-room, management-presentation, and diligence-response support
  • Specialist support alongside bankers, legal counsel, accounting firms, and generalist commercial-diligence teams
  • Transaction and valuation support

How We Engage

We can lead an integrated diligence process or provide a focused scientific, clinical, reimbursement, or commercial workstream alongside the existing transaction team. Engagements may cover pre-process preparation, live diligence, transaction support, or post-close integration and value creation.

Let’s Create Your Success Story

If you’re ready to achieve measurable results and take your strategy to the next level, Charrette Advisory is here to help.

(914) 953-4051